{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:59:39Z","timestamp":1787759979801,"version":"build-2784847793"},"reference-count":35,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study was conducted among participants with episodic migraine, to (i) assess patient preferences for attributes associated with calcitonin gene\u2010related peptide\u2010targeting therapies to prevent migraine and (ii) predict the probability that a real\u2010world patient would prefer an atogepant\u2010like treatment profile over monoclonal antibody\u2010like profiles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Calcitonin gene\u2010related peptide\u2010targeting therapies have emerged as safe and effective first\u2010line preventive treatments for migraine. Given the expansion of the treatment landscape, it is important to understand what drives treatment choices among patients with migraine. However, few studies have quantified patient preferences for attributes of preventive treatments for migraine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A discrete\u2010choice experiment survey was administered to adults (aged 18\u201380\u2009years and &lt;50\u2009years at age of migraine onset) with episodic migraine who were na\u00efve to calcitonin gene\u2010related peptide\u2010targeting therapies between November and December 2020. Respondents were presented with pairs of hypothetical treatment profiles defined by seven attributes with varying levels. Preference weights were used to estimate the conditional relative importance of each attribute and the probability that an average respondent in the sample would prefer an atogepant\u2010like treatment relative to monoclonal antibody\u2010like treatment profiles. No a priori hypotheses were evaluated related to treatment preference.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Across the attributes and levels included in the study, the relative importance estimates revealed that, on average, the two most important changes in treatment attributes were (i) having a treatment with no nausea instead of a treatment with moderate\u2010to\u2010severe nausea and (ii) having a treatment administered by oral pill or tablet instead of a self\u2010injection once every month or intravenous infusion once every 3\u2009months. For example, respondents valued having a treatment administered by daily oral pill instead of by quarterly intravenous infusion ~2.5 times more than avoiding a treatment with mild nausea. The predicted probability that an average respondent in the sample would prefer an oral, once\u2010daily atogepant\u2010like profile was higher than the predicted probability that an average respondent in the sample would prefer a specific monoclonal antibody\u2010like injectable profile (range, 70.9%\u201385.4%) or a composite profile representing monoclonal antibodies as a class of drugs (range, 70.7%\u201373.8%), even when efficacy of the monoclonal antibody\u2010like profile was similar to the atogepant\u2010like profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Relative importance estimates suggest that, on average, respondents with episodic migraine preferred an oral pill over monthly or quarterly injections and infusions. Respondents also preferred to avoid treatment\u2010related nausea and constipation. The predicted choice probability results further suggest a preference for a daily oral pill, given that seven of 10 respondents, on average, would prefer a profile similar to atogepant over profiles similar to monoclonal antibodies administered intravenously or by self\u2010injection.<\/jats:p><\/jats:sec>","DOI":"10.1111\/head.14974","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T06:20:31Z","timestamp":1750746031000},"page":"1541-1553","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete\u2010choice experiment"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-2897","authenticated-orcid":false,"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[{"name":"Department of Neurology Albert Einstein College  Bronx New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research AbbVie, Inc.  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Myers","sequence":"additional","affiliation":[{"name":"Health Preference Assessment RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cooper","family":"Bussberg","sequence":"additional","affiliation":[{"name":"Health Preference Assessment RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Stokes","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research AbbVie, Inc.  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Nahas","sequence":"additional","affiliation":[{"name":"Department of Neurology Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13281"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/nedt.2006.2.3.281"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13498"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12142"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14255"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"e_1_2_11_11_1","unstructured":"FDA (Food and Drug Administration).Patient preference information\u2014voluntary submission review in premarket approval applications humanitarian device exemption applications and de novo requests and inclusion in decision summaries and device labeling: guidance for industry food and drug administration staff and other stakeholders.2016. Accessed March 8 2018.https:\/\/www.fda.gov\/media\/92593\/download."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_11_14_1","unstructured":"Teva Pharmaceuticals USA Inc.AJOVY\u00ae (fremanezumab\u2010vfrm) injection. October 2022. Accessed September 3 2024.https:\/\/www.ajovyhcp.com\/globalassets\/ajovyhcp\/ajovy\u2010pi.pdf."},{"key":"e_1_2_11_15_1","unstructured":"Amgen Inc.AIMOVIG\u00ae(erenumab\u2010aooe) injection for subcutaneous use. August 2024. Accessed October 29 2024.https:\/\/www.pi.amgen.com\/\u2010\/media\/Project\/Amgen\/Repository\/pi\u2010amgen\u2010com\/Aimovig\/Aimovig_pi_hcp_english.pdf."},{"key":"e_1_2_11_16_1","unstructured":"Eli Lilly and Company.EMGALITY \u2013 galcanezumab\u2010gnlm injection solution March 2021. Accessed September 3 2024.https:\/\/uspl.lilly.com\/emgality\/emgality.html#pi."},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/002224379403100408"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocm.2015.09.001"},{"key":"e_1_2_11_20_1","unstructured":"LouviereJJ HensherDA SwaitJD.Stated Choice Methods: Analysis and Applications. Cambridge University United Kingdom;2000."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1697"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0734-2"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/11539650-000000000-00000"},{"key":"e_1_2_11_24_1","volume-title":"Discrete Choice Methods with Simulation","author":"Train KE","year":"2009"},{"key":"e_1_2_11_25_1","unstructured":"TrainKE SonnierGP.Mixed Logit with Bounded Distributions of Partworths. Presented.2003."},{"key":"e_1_2_11_26_1","unstructured":"TrainK.Halton Sequence for Mixed Logit.1999."},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajae.12311"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(20)30234-9"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-014-4044-2"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.33393\/dti.2021.2342"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0135-0"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-023-00649-4"},{"key":"e_1_2_11_33_1","unstructured":"FDA. Food and Drug Administration.Factors to consider when making benefit\u2010risk determinations in medical device premarket approval and de novo classifications. Guidance for industry and food and drug administration staff (FDA\u20102011\u2010D\u20100577).2019. Accessed August 12 2024.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/factors\u2010consider\u2010when\u2010making\u2010benefit\u2010risk\u2010determinations\u2010medical\u2010device\u2010premarket\u2010approval\u2010and\u2010de."},{"key":"e_1_2_11_34_1","unstructured":"EMA (European Medicines Agency).EMA Regulatory Science to 2025.2020. Accessed August 12 2024.https:\/\/www.ema.europa.eu\/en\/about\u2010us\/how\u2010we\u2010work\/regulatory\u2010science\u2010strategy."},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14709"},{"key":"e_1_2_11_36_1","unstructured":"BioPharmaceuticals Inc.VYEPTITM (eptinezumab\u2010jjmr) Injection for Intravenous Use. February 2020. Accessed September 3 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761119s000lbl.pdf."}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:34:12Z","timestamp":1760556852000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/head.14974"],"URL":"https:\/\/doi.org\/10.1111\/head.14974","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"2024-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}